A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the ...

CVS Health is not entitled to coverage from insurers, including AIG and Chubb , against thousands of lawsuits over its role ...

CVS Health is not entitled to coverage from insurers, including AIG and Chubb, against thousands of lawsuits over its role in ...

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

CVS Health (CVS) won’t add Gilead’s (GILD) new HIV prevention drug to its commercial plans for now, despite the medication’s proven effectiveness, a spokesperson tells Reuters, Deena Beasley reports.

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

By Amina Niasse NEW YORK (Reuters) -CVS Health beat Wall Street estimates for second-quarter profit on Thursday, as tight oversight of higher medical costs led to improved performance for its ...